Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024

Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2024. The full report can be found here.

Chris Cargill, President and CEO of Nxera, commented: “We entered 2024 with a clear vision to capitalize on a number of strategic opportunities and build on the strong foundations we have created, positioning the business for the next stage of its journey to become a leading biopharmaceutical company in Japan. The last three months, defined by our bold actions, have been a testament to this.

“A key milestone this quarter has been the change of company name from Sosei Heptares to Nxera Pharma and the unveiling of a bold new brand and identity that captures our ambition to be pioneers of the next era of biopharmaceuticals and medicine. The decision to make this change was driven by the significant growth and development of the business, which has been accelerated through several key strategic acquisitions in recent years, and progress made advancing our extensive pipeline both in-house and with our partners.

“I extend my gratitude to our brilliant team in Japan, the UK, South Korea and Switzerland whose dedication and expertise has enabled these significant achievements and will empower our future success.”

Operational Highlights for Q1 2024

Corporate highlights

• Change of company name to Nxera Pharma
  • Approved on 27 March at the Company’s 34th Annual Shareholders’ Meeting and came into effect on 1 April 2024
• Appointment of Chief Operating Officer, Toshihiro Maeda
  • Mr Maeda, an experienced pharmaceutical executive, is leading the post-acquisition integration of the Nxera Pharma Japan (“NPJ”) and Nxera Pharma Korea (“NPK”) businesses into Nxera and will be responsible for all technical operations

Progress with in-house programs

• First subject dosed in a Phase 1 trial with NXE0033744, a novel, potent, selective and gut-restricted EP4 receptor agonist discovered by Nxera in development for the treatment of Inflammatory Bowel Disease (IBD)
• Regained full ownership from GSK of NXE0027477, a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in development as a potential new treatment for IBD
  • Nxera expects to determine the optimal strategy for further clinical development of the program, which could include in-house development and/or re-partnering

Progress with partnered programs